COVID-19 antigens for PoC test development
Our group has extensive expertise in the expression of viral glycoprotein antigens, manipulation of protein sequences to enhance expression and optimisation of purification methods. In this project we will express both the spike and nucleoproteins of COVID-19 and other coronaviruses. These antigens will contribute to the development of a COVID-19 point-of-care diagnostic test.
Objective
We will contribute to the development of a point-of-care (PoC) COVID-19 test by providing novel technology to alter antigen structure and enhance the sensitivity of PoC tests that can be monitored by biolayer interferometry.
Approach
We have commenced a large project to express both the spike and nucleoproteins of COVID-19 and other coronaviruses including SARS, MERS, OC43, 229E, NL63, and HKU1. The antigens will be provided to Burnet’s Global Health Diagnostics Development Group for development of a COVID-19 point-of-care (PoC) diagnostic test.
Partners
Funding partners
Victorian Government (part of $1m for Diagnostics Development)
Project team
Professor Heidi Drummer
Scientific Director for Research Translation; Scientific Director, Burnet Diagnostics Initiative; Principal Investigator, Burnet Vaccine Initiative; Co-Head, Viral Entry and Vaccines Group
